Skip to main content
OpenTrials
Completed

NCT Number: NCT06623773

Study on Structum® in Adult Patients With Osteoarthritis (TRUST)

Chondroitin sulfate (CS) is a Symptomatic Slow Acting Drugs for OsteoArthritis (SYSADOA) and a natural biomacromolecule belonging to the class of glycosaminoglycans. CS is a major component of the extracellular matrix (ECM), where it constitutes an essential component of proteoglycans.

To this date, no real-world studies have been conducted to precisely describe the burden associated with osteoarthritis (OA) among patients treated with CS.Therefore, an observational, descriptive, prospective, national study will be conducted to describe the burden associated with OA and the quality of life of patients treated with Structum® in Poland.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Osteoarthritis, Knee Arthritis Joint Diseases Musculoskeletal Diseases Osteoarthritis Rheumatic Diseases

Age range

50 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Maciej Dołżyński, Bialystok, Poland

Loading trial locations.

About this study

This is an observational, descriptive, national, multicentric (11 centres), prospective, longitudinal study, which will be conducted over a 6-month follow-up period for each patient. The study will not provide or recommend any specific treatment or procedures.

All patients affected by OA in the knee, for whom Structum® is prescribed in a participating center, will be screened in a consecutive manner for eligibility. The study will focus exclusively on patients with OA in the knee as this is the joint most frequently affected and most easily assessed for OA patients.

Two additional data collections can be anticipated for these patients as part of their standard of care follow-up visits, which will usually occur around 3 and 6 months after the initial study visit.The patient enrolment period is expected to be 6 months, with a total study duration of 12 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female patients aged 50 to 85 years at inclusion
  • of knee OA (either a patient newly diagnosed [at inclusion] or with history of knee OA) based on at least the following items 1 and/or 2:
  • knee pain lasting for at least 3 months;
  • patient in the active phase of knee OA disease (knee pain score ≥ 40mm at inclusion on the Visual Analog Scale [VAS] 0-100 mm);
  • knee radiographs showing knee joint narrowing and/or osteophytes.
  • Patients who have been prescribed, for the first time or not, Structum®.
  • patient taking any non-steroidal anti-inflammatory drugs (NSAIDs) or other analgesics should be on stable dose at least one week before inclusion to the study.
  • Patients able to visit the clinic and attend follow-up visits.
  • Patients having signed an informed consent form, according to local regulations.

Exclusion criteria

  • Patients with any ongoing chondroitin sulfate treatment at inclusion or during the last 3 months.
  • plasma (in the last 3 months). No glucocorticoids administration in the last 3 months before inclusion. That does not include NSAIDS, paracetamol and other analgesic medications (e.g. tramadol).
  • Patients with an artificial knee joint, including unilateral.
  • Patients scheduled to undergo knee replacement surgery in the next 6 months.
  • Patients with a severe general condition that prevents them from being included in the study as assessed by the investigator.
  • Patients participating in interventional trials on investigational drugs at the time of inclusion.

Treatment and study plan

chondroitin sulfate

Drug

Chondroitin sulfate (CS) is a natural biomacromolecule belonging to the class of glycosaminoglycans and is an unbranched complex polysaccharide consisting of a repeating disaccharide structure of glucuronic acid and N-acetyl-D-glucosamine [18]. It is a major component of the extracellular matrix (ECM), where it constitutes an essential component of proteoglycans. Oral bioavailability of CS has been demonstrated [19], and its use for the treatment of OA has been established in animal models [20], as well as in clinical trials [21, 22]. CS, is available as a pharmaceutical grade drug (Structum®), meaning that the product is manufactured under Good Manufacturing Practices (GMP) conditions, and is in excess of 99% purity with no binders, fillers, excipients, dyes, or unknown substances. According to the Instructions for Use (IFU), the recommended posology for Structum® is 500 mg twice daily.

Other names: Structum

Primary outcomes

  1. Osteoarthritis (OA) Symptom Severity (Pain, Stiffness and Function) as Assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Questionnaire, for Patients With Knee OA and Treated With Structum®, at Baseline

    Time frame: At baseline (inclusion)

    Description of knee OA symptom severity per the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Questionnaire.

    The total WOMAC score range is from 0-2400, with higher scores indicating worse pain, stiffness, and functional limitations.

  2. Charlson Comorbidity Index Score Measured at Baseline

    Time frame: At baseline (inclusion)

    The Charlson Comorbidity Index (CCI) is a scoring system used to predict mortality risk in patients with multiple comorbidities. The index evaluates 17 conditions, with each condition assigned a score based on its severity and the risk of mortality associated with it. The score is rated from 0 to 37. A higher score indicates a higher number of comorbidities.

  3. Treatment History Received by the Patients in the Past 6 Months Before Inclusion

    Time frame: From 6 months before inclusion to inclusion (baseline)

    Treatment history corresponds to the treatment received or not (yes/no) for knee osteoarthritis in the past 6 months before inclusion in the study

Secondary outcomes

  1. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score at 3 Months

    Time frame: From baseline (inclusion) to 3 months after baseline

    Total score of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Questionnaire. Total score at 3 months and mean difference from baseline to 3 months are provided.

    The total WOMAC score range is from 0-2400, with higher scores indicating worse pain, stiffness and functional limitations.

  2. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score at 6-months

    Time frame: From baseline to 6 months after baseline

    Total score of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Questionnaire. Total score at 6 months and mean difference from baseline to 6 months are provided.

    The total WOMAC score range is from 0-2400, with higher scores indicating worse pain, stiffness, and functional limitations.

  3. BONe's Questionnaire at Baseline

    Time frame: At baseline (inclusion)

    Mean global score of the osteoarthritis burden of the Burden Osteoarthritis New'Scale (BONe'S). The total score range is 0-100 scale. Higher scores represent a heavier burden.

  4. BONe's Outcome at 3 Months

    Time frame: From baseline (inclusion) to 3 months after baseline

    Mean global score of the OA burden of the Burden Osteoarthritis New'Scale (BONe'S).The total score range is 0-100 scale. Higher scores represent a heavier burden.

    Global score at 3 months and mean difference from baseline to 3 months are provided.

  5. BONe's Outcome at 6 Months

    Time frame: From baseline (inclusion) to 6 months after baseline

    Mean global score of the OA burden of the Burden Osteoarthritis New'Scale (BONe'S). The total score range is 0-100 scale. Higher scores represent a heavier burden.

    The Global score at 6 months and the mean difference from baseline to 6 months are provided.

  6. Short Form Questionnaire With 12 Questions (SF-12): Physical Score Component at Baseline

    Time frame: At baseline (inclusion)

    Global score of general health (physical score component) of the Short Form Questionnaire with 12 questions (SF-12) Scores range from 0 to 100, with higher scores indicating a better physical functioning.

  7. Short Form Questionnaire With 12 Questions (SF-12) Outcome: Physical Score Component at 3 Months

    Time frame: From baseline to 3 months after baseline

    Global score of general health (physical score component) of the Short Form Questionnaire with 12 questions (SF-12). Scores range from 0 to 100, with higher scores indicating better physical functioning.

    Global score at 3 months and mean difference from baseline to 3 months are provided.

  8. Short Form Questionnaire With 12 Questions (SF-12): Physical Score Component at 6 Months

    Time frame: From baseline to 6 months after baseline

    Global score of general health (physical score component) of the Short Form Questionnaire with 12 questions (SF-12). Scores range from 0 to 100, with higher scores indicating better physical functioning.

    Global score at 6 months and mean difference from baseline to 6 months are provided

  9. Short Form Questionnaire With 12 Questions (SF-12): Mental Score Component at Baseline

    Time frame: Baseline

    Global score of mental score component of the Short Form Questionnaire with 12 questions (SF-12). Scores range from 0 to 100, with higher scores indicating a better mental health functioning.

  10. Short Form Questionnaire With 12 Questions (SF-12): Mental Score Component at 3 Months

    Time frame: From baseline to 3 months after baseline

    Global score (mental score component) of the Short Form Questionnaire with 12 questions (SF-12). Scores range from 0 to 100, with higher scores indicating a better mental health functioning.

    Global score at 3 months and mean difference from baseline to 3 months are provided.

  11. Short Form Questionnaire With 12 Questions (SF-12): Mental Score Component at 6 Months

    Time frame: From baseline to 6 months

    Global score (mental score component) of the Short Form Questionnaire with 12 questions (SF-12). Scores range from 0 to 100, with higher scores indicating a better mental health functionning. Global score at 6 months and mean difference from baseline to 6 months are provided.

  12. Persistence Outcomes at 3 Months

    Time frame: At 3 months after baseline

    Proportion of patients with ongoing Structum® prescription at 3 months

  13. Persistence Outcomes at 6 Months

    Time frame: At 6 months after baseline

    Proportion of patients with ongoing Structum® prescription at 6 months

  14. Global Score of Patients Satisfaction, After First Dose of Structum®, at 3 Months

    Time frame: At 3 months after baseline

    Global statisfaction score of patient at 3 months, as assessed by Structum® treatment satisfaction questionnaire. The Global satisfaction score ranges from 0 to 100. A higher score indicates a higher satisfaction.

  15. Global Score of Patient Satisfaction, After First Dose of Structum®, at 6 Months

    Time frame: At 6 months after baseline

    Global satisfaction score of patient at 6 months, as assessed by Structum® treatment satisfaction questionnaire. The Global satisfaction score range from 0 to 100. A higher score indicates a higher satisfaction.

Other outcomes

  1. Spearman Correlation Coefficient Value for the Correlation Between the BONe'S Questionnaire and the Short Form Questionnaire, SF-12 Questionnaire (Physical and Mental Component) at Inclusion.

    Time frame: Baseline (inclusion)

    The interpretation of the correlation coefficient is as follows:

    <0.5: weak correlation 0.5-0.6: mild correlation 0.6-0.7: moderate correlation >0.7: strong correlation Of note, values of the coefficient could be positive or negative

  2. Spearman Correlation Coefficient Value for the Correlation Between the BONe'S Questionnaire and the SF-12 Questionnaire (Physical and Mental Components) at 3 Months

    Time frame: At 3 months after baseline

  3. Spearman Correlation Coefficient for the Correlation Between the BONe'S Questionnaire and the Short Form, SF-12 Questionnaire at 6 Months.

    Time frame: At 6 months after baseline

    The interpretation of the correlation coefficient is as follows:

    <0.5: weak correlation 0.5-0.6: mild correlation 0.6-0.7: moderate correlation >0.7: strong correlation

  4. Spearman Correlation Coefficient for the Correlation Between the BONe'S Questionnaire and the WOMAC Questionnaire at Inclusion

    Time frame: Baseline (inclusion)

    The interpretation of the correlation coefficient is as follows:

    <0.5: weak correlation 0.5-0.6: mild correlation 0.6-0.7: moderate correlation >0.7: strong correlation

  5. Spearman Correlation Coefficient and P Value for the Correlation Between the BONe'S Questionnaire and the WOMAC Questionnaire at 3 Months

    Time frame: At 3 months after baseline

    The interpretation of the correlation coefficient is as follows:

    <0.5: weak correlation 0.5-0.6: mild correlation 0.6-0.7: moderate correlation >0.7: strong correlation

  6. Spearman Correlation Coefficient Value for the Correlation Between the BONe'S Questionnaire and the WOMAC Questionnaire at 6 Months.

    Time frame: At 6 months after baseline

    The interpretation of the correlation coefficient is as follows:

    <0.5: weak correlation 0.5-0.6: mild correlation 0.6-0.7: moderate correlation >0.7: strong correlation

  7. Change in NSAIDs and Other Analgesics at Inclusion Compared to 6 Months Before Inclusion

    Time frame: Baseline (inclusion)

    Description of the proportion of patients with a change in their prescription of NSAIDs and other analgesics at inclusion, compared to 6 months before inclusion, with a change being defined as any change of the daily dose of NSAIDs (calculated from the frequency of intake and the dose of each intake)

    • Increased
    • Stable
    • Decreased

  8. Changes in NSAIDs and Other Analgesics at 3 Months Compared to Inclusion

    Time frame: From baseline to 3 months after baseline

    Proportion of patients with changes in the prescription of NSAIDs and other analgesics at 3 months compared to inclusion

  9. Change in NSAIDs and Other Analgesics at 6 Months Compared to Inclusion

    Time frame: From baseline to 6 months after baseline

    Proportion of patients with changes in the prescription of NSAIDs and other analgesics at 6 months compared to inclusion

Sponsors and collaborators

Lead sponsor

Pierre Fabre Medicament

Industry

Registry information

Official study title

Prospective Non-Interventional Study on Structum® in Adult Patients With Osteoarthritis

Acronym: TRUST

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Oct 2, 2024
Registry last updated
Sep 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.